Program Book - Confex

ACR/ARHP Poster Session B
11
Northwestern University Feinberg School of Medicine,
Chicago, IL, 12 Hanyang University Hospital for Rheumatic
Diseases, Clinical Research Center for Rheumatoid Arthritis
(CRCRA), Seoul, South Korea, 13 Dalhousie University, Halifax,
NS, 14 University Health Network/Mount Sinai Hospital,
Toronto, ON, 15 Research Institute of the McGill Univ. Health,
Montreal, QC, 16 Feinstein Institute for Medical Research,
Manhasset, NY, 17 Allegheny Singer Research Institute,
Pittsburgh, PA, 18 Toronto Western Hospital and University of
Toronto, Toronto, ON, 19 Toronto Western Research Institute,
University of Toronto, University Health Network, Toronto,
ON, 20 UCSD School of Medicine, La Jolla, CA, 21 North Dallas
Dermatology Assoc, Dallas, TX, 22 University of Maryland,
Baltimore, MD, 23 Chicago
1384. Predictors of Earlier Time to Renal Failure Among Those
with Biopsy-Proven Lupus Nephritis. Alí Duarte-García 1 ,
Hong Fang 1 , Laurence S. Magder 2 and Michelle Petri 1 , 1 Johns
Hopkins University School of Medicine, Baltimore, MD,
2
University of Maryland, Baltimore, MD
1385. Do Active Lupus Patients Continue to Improve At 12
Months by Systemic Lupus Erythematous Disease Activity
Index 2000 Responder Index 50 (SRI-50) Zahi Touma 1 ,
Murray B. Urowitz 1 , Dominique Ibanez 1 , Shahrzad Taghavi-
Zadeh 1 and Dafna D. Gladman 2 , 1 Toronto Western Hospital
and University of Toronto, Toronto, ON, 2 Toronto Western
Hospital, University of Toronto, Toronto, ON
1386. Lupus Disease Activity Does Not Improve Significantly in
One System and Worsen in Another System. Zahi Touma 1 ,
Dafna D. Gladman 2 , Dominique Ibanez 1 , Shahrzad Taghavi-
Zadeh 1 and Murray B. Urowitz 1 , 1 Toronto Western Hospital
and University of Toronto, Toronto, ON, 2 Toronto Western
Hospital, University of Toronto, Toronto, ON
1387. Low Placebo Responses and Clinical Components of the
Biomarkers of Lupus Disease (BOLD) Study May Provide
Useful Insights for SLE Clinical Trial Design. Sudhakar T.
Sridharan 1 , T. Zhou 1 , F. Immermann 1 , M. Lehmann 1 , J.L.
Masferrer 1 , M. Honczarenko 1 , J.C. Rawdon 2 , J.A. James 2 and
J.T. Merrill 2 , 1 Pfizer Inc, Collegeville, PA, 2 Oklahoma Medical
Research Foundation, Oklahoma City, OK
1388. Frequency and Characteristics of Prolonged Remission
in Systemic Lupus Erythematosus. Amanda J. Steiman 1 ,
Murray B. Urowitz 1 , Dominique Ibanez 1 , Anjali Papneja 2
and Dafna D. Gladman 3 , 1 Toronto Western Hospital and
University of Toronto, Toronto, ON, 2 University of Toronto,
Toronto, ON, 3 Toronto Western Hospital, University of
Toronto, Toronto, ON
1389. Comparison of the SF-36 Vs. Lupus Qol in Measuring
Health-Related Quality of Life in Systemic Lupus
Erythematosus Women with and without Activity. Claudia
Mendoza-Pinto 1 , Mario Garcia-Carrasco Sr. 1 , Socorro
Mendez-Martinez 1 , Oscar Pazarán 1 , Mario H. Cardiel 2
and Aurelio Lopez-Colombo 3 , 1 HGR 36 CMN Manuel Ávila
Camacho, Instituto Mexicano del Seguro Social, Puebla,
Mexico, 2 Hospital, Morelia, Mexico, 3 Delegación Estatal,
Instituto Mexicano del Seguro Social, Puebla, Mexico
1390. Cognitive Dysfunction and Diffusion Tensor Imaging in
Systemic Lupus Erythematosus. Elizabeth Kozora 1 , Aziz
Ulug 2 , Doruk Erkan 3 , Glendalee Ramon 3 , An Vo 4 , Robert
Zimmerman 5 , Emily Duggan 1 , JoAnn Vega 3 , Christopher
Filley 6 and Michael D. Lockshin 3 , 1 National Jewish Health,
Denver, CO, 2 The Feinstein Institute for Medical Research,
Manhasset, NY, 3 Barbara Volcker Center for Women and
Rheumatic Diseases: Hospital for Special Surgery, New York,
NY, 4 The Feinstein Institute for Medical Reearch, Manhasset,
NY, 5 Weill Cornell Medical College, New York, NY, 6 University
of Colorado School of Medicine, Aurora, CO
1391. Impaired Responses to Aspirin in Patients with Systemic
Lupus Erythematosus: The Role of Inflammation and
Oxidative Stress. Vivian K. Kawai 1 , Ingrid B. Avalos 2 , Annette
M. Oeser 1 , John A. Oates 1 , Ginger L. Milne 1 , Cecilia P. Chung 3
and C. Michael Stein 1 , 1 Vanderbilt University, Nashville, TN,
2
Harvard University, Boston, MA, 3 Vanderbilt Medical Center,
Nashville, TN
1392. Infection As a Predictor of Organ System Damage Accrual
and/or Death in Systemic Lupus Erythematosus. Amanda
Eudy 1 , Deanna Hill 2 , Qinggong Fu 2 , Hong Fang 3 and Michelle
Petri 3 , 1 UNC Chapel Hill, Chapel Hill, NC, 2 GlaxoSmithKline,
Collegeville, PA, 3 Johns Hopkins University School of
Medicine, Baltimore, MD
1393. Low Prevalence of Use of ACEI/ARBS and Lipid Lowering
Agents In African American(AA) SLE Patients. Asha Thomas,
Madhu-Kalyan Pendurthi and Vikas Majithia, University of
Mississippi Medical Center, Jackson, MS
1394. Population Pharmacokinetics of Sifalimumab, An
Investigational Anti-Interferon-á Monoclonal Antibody, in
Systemic Lupus Erythematosus Patients. Rajesh Narwal,
Lorin Roskos, Wendy White, Warren Greth and Gabriel
Robbie, MedImmune, Gaithersburg, MD
1395. Do Race/Ethnicity and Geography Affect Outcomes in
An Inception Cohort of Patients with Systemic Lupus
Erythematosus Followed for At Least 5 Years D. D.
Gladman 1 , Murray B. Urowitz 1 , Dominique Ibanez 1 , Nicole
Anderson 1 and Systemic Lupus International Collaborating
Clinics (SLICC) 2 , 1 Toronto Western Hospital and University of
Toronto, Toronto, ON, 2 Toronto, ON
1396. Microstructural Abnormalities in White and Deep Gray
Matter Visualized within the First Year of Diagnosis in
Adolescents with SLE: A Pilot Magnetization Transfer
Imaging Study. Eyal Muscal 1 , Elfrides Traipe 1 , Elisabeth
Wilde 1 , Douglas R. Bloom 1 , Barry L. Myones 1 , Zili D. Chu 1 ,
Robin L. Brey 2 and Jill Hunter 1 , 1 Baylor College of Medicine,
Houston, TX, 2 UTHSCSA, San Antonio, TX
1397. Lupus and Body Image: An Intervention That Works.
Meenakshi Jolly 1 , Kristin Peters 2 , Rachel A. Mikolaitis 1 , Kali
Evans-Raoul 3 , Thomas F. Cash 4 and Joel A. Block 1 , 1 Rush
University Medical Center, Chicago, IL, 2 University of
Missouri Health Care, Columbia, MO, 3 The Image Studios,
Chicago, 4 Old Dominion University, Norfolk, VT
2011 Program Book 235